Home › NCT03910569
The Cedars-Sinai Smidt Heart Institute Takotsubo Registry & Proteomic Study
Smidt Heart Institute Takotsubo Registry
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Have received a diagnosis of Takotsubo from their physician and consent to enroll * Submit full medical records needed for Takotsubo adjudication Exclusion Criteria: * Younger than 18 years * Unable to provide informed consent * Unable to provide the necessary documentation needed for screening purposes
About the study
The Cedars-Sinai SHI Takotsubo Registry and Proteomic Study is an observational registry that will collect retrospective and prospective demographic, clinical, hemodynamic, laboratory and other diagnostic parameters, therapy and outcome data from individuals who meet the inclusion/exclusion criteria of Takotsubo Registry protocol. Subjects will also be invited to provide a blood sample utilizing a Mitra kit sent to their homes. Researchers from the Barbra Streisand Women's Heart Center will analyze Registry data to identify Takotsubo phenotypes, improve diagnostic capabilities, better predict recurrence rates, and develop targeted Takotsubo treatments.
Sponsor: Cedars-Sinai Medical Center · Participants: 1,000 · Started: Jan 3, 2019
Contact the study team
- TS Registry · Phone: 310-248-8563
- BS WHC, MS · Phone: 310-423-9666
Official record on ClinicalTrials.gov — NCT03910569
Locations in the U.S.
| California | Cedars Sinai Medical Center, Los Angeles |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.